NCT02762500 is a Phase 2 clinical trial of LYC-30937-EC in Colitis, Ulcerative, sponsored by Lycera Corp..

Who is sponsoring NCT02762500?

NCT02762500 is sponsored by Lycera Corp..

What drugs are being tested in NCT02762500?

Interventions in NCT02762500: LYC-30937-EC, Placebo.

What condition does NCT02762500 study?

NCT02762500 studies Colitis, Ulcerative.

Is NCT02762500 still recruiting?

NCT02762500 is currently completed. Last updated 11 March 2019.

Are results published for NCT02762500?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2019-03-11 · How we verify

NCT02762500

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Assess the Efficacy and Safety of Induction Therapy With LYC-30937-EC in Subjects With Active Ulcerative Colitis

Completed Phase 2 Results posted Last updated 11 March 2019

What this trial tests

Phase 2 trial testing LYC-30937-EC in Colitis, Ulcerative in 124 participants. Completed in 1 May 2018.

Timeline

1 July 2016

Primary endpoint
1 May 2018

1 May 2018

Quick facts

Lead sponsor	Lycera Corp.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	124
Start date	1 July 2016
Primary completion	1 May 2018
Estimated completion	1 May 2018
Sites	71 locations across United States, Canada, Czechia, Hungary, Netherlands, Poland, Serbia

Drugs / interventions tested

LYC-30937-EC — full drug profile →
Placebo

Conditions studied

Colitis, Ulcerative — all drugs for Colitis, Ulcerative →

Sponsor

Lycera Corp. — full company profile →

Who can join

Adults 18 to 75, any sex, with Colitis, Ulcerative. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Number of Subjects Who Achieve Clinical Remission at Week 8 Using Modified Mayo Score.
Time frame: 8 weeks
The modified Mayo score is a tool designed to measure disease activity for ulcerative colitis. Scoring ranges from 0 to 9 points and consists of 3 subscores (stool frequency, rectal bleeding, endoscopy), each graded 0 to 3 with higher score indicating more severe disease activity. Endoscopy scoring was performed centrally. Clinical remission on the modified Mayo score was defined as a Mayo stool

Sponsor's own description

The purpose of the study is to evaluate the efficacy and safety of LYC-30937-EC given orally once daily in subjects with active ulcerative colitis (UC) defined as a total Mayo score (TMS) of 4-11 inclusive, with an endoscopic score of ≥ 2 and a rectal bleeding score of ≥ 1 at screening.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Advancing therapeutic frontiers: a pipeline of novel drugs for UC management.
Bertin L, Massano A, Redavid C, Scarpa M, et al · · 2026 · PMID 41822012 · DOI 10.3389/fgstr.2026.1747118

Verify or expand the search:

Other trials of LYC-30937-EC

Trials testing the same drug.

NCT02764229 — Open-label Extension Study to Assess Safety and Tolerability of LYC-30937-EC in Subjects With Active Ulcerative Colitis · Phase 2 · terminated

Other recruiting trials for Colitis, Ulcerative

Currently open trials in the same condition.

NCT07302360 — A Real-World Study of Guselkumab in Chinese Participants With Ulcerative Colitis · recruiting
NCT07242248 — A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disea · recruiting
NCT07196748 — A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Col · Phase 3 · recruiting
NCT07102368 — A Study to Generate Real-world Evidence of Guselkumab Effectiveness in Inflammatory Bowel Disease in Germany · recruiting
NCT06651281 — Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Coli · Phase 3 · recruiting

Other Lycera Corp. trials

Trials by the same sponsor.

NCT03396497 — Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer · Phase 1 · unknown
NCT02872285 — An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis · Phase 2 · completed
NCT02764229 — Open-label Extension Study to Assess Safety and Tolerability of LYC-30937-EC in Subjects With Active Ulcerative Colitis · Phase 2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02762500 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Lycera Corp.
Last refreshed: 11 March 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02762500.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing